Cover Story
The FDA Oncologic Drugs Advisory Committee Feb. 26 voted down a vascular-targeted photodynamic therapy for early-stage, low-risk prostate cancer and, in a narrow vote, recommended approval for a combination of a VEGF receptor 2 antagonist and an EGFR-targeting tyrosine kinase inhibitor for front-line treatment of EGFR-positive non-small cell lung cancer.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Radiation oncologist, global health expert C. Norman Coleman dies of sarcoma at 79
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Kathy Giusti’s “Fatal to Fearless” memoir tells the story of prevailing over multiple myeloma
Book offers 12 steps to beating cancer in a broken medical system - Population scientist Monica Baskin is the “Jackie Robinson” of cancer center deputy directors
- Biden’s State of the Union highlights healthcare wins in cancer
White House announces ARPA-H precision cancer therapy program and patient navigation commitments - CMS starts paying for patient navigation; ACS offers navigation credentialing program